Abstract: Cancer remains a significant threat to global health. While traditional treatments like surgery, radiotherapy, and chemotherapy have improved survival rates, patients with advanced stages often face poor outcomes or prohibitive costs. Oncolytic viruses (OVs)—genetically engineered or naturally occurring viruses that selectively replicate in and destroy cancer cells while sparing healthy tissue—offer a promising new strategy. This review examines the clinical applications of OVs, including herpes simplex virus and adenovirus, and evaluates the future of oncolytic virotherapy by analyzing its current advantages and limitations.
Note on Document Status: This paper was officially RETRACTED by the journal Frontiers in Oncology on September 9, 2020. While this summary outlines the technical content presented, the findings should be viewed with caution as the scientific community has flagged issues with the original publication.
Introduction: The Third Revolution in Oncology
Oncolytic Virotherapy is often described as the "third revolution" in cancer treatment. Unlike traditional therapies that can be limited by systemic toxicity and drug resistance, OVs exploit the natural defects in cancer cell antiviral signaling—such as impaired Type I interferon pathways—to replicate selectively within tumors. This approach aims for high killing efficiency with precise targeting and minimal side effects.
Mechanism of Action: Turning "Cold" Tumors "Hot"
OVs act as a dual-threat approach. Beyond direct cell lysis (physical destruction of the cancer cell), they serve as potent "immune primers." When a cancer cell is lysed, it releases Damage-Associated Molecular Patterns (DAMPs) and tumor-derived antigens. This process effectively "unmasks" the tumor, allowing the host's immune system to recognize and attack distant, uninfected metastatic sites.
To overcome the body's natural tendency to neutralize viruses before they reach the tumor, researchers are exploring "Trojan Horse" delivery systems. These involve using carrier cells, such as stem cells or Cytokine-Induced Killer (CIK) cells, to shield the virus during systemic circulation.
Diagnostic Potential (Theranostics)
OVs are also being developed as diagnostic tools. By inserting reporter genes—such as Luciferase, Green Fluorescent Protein (GFP), or the human sodium-iodine symporter (hNIS) gene—into the viral genome, clinicians can visualize tumor margins and small metastases in real-time using PET, SPECT, or MRI. For example, OVs expressing the hNIS gene have successfully allowed for the detection of gastric cancer metastases that were otherwise invisible to standard CT scans.
Clinical Landscape and Efficacy
The paper synthesizes data from numerous clinical trials, highlighting several major products currently in use or under investigation. Key results include:
- Oncorine (H101): In trials for head and neck cancer, combining Oncorine with chemotherapy resulted in a 78.8% response rate, compared to 39.6% for chemotherapy alone.
- T-VEC (Imlygic): The first FDA-approved OV, showing a 26% overall response rate in advanced melanoma.
- Rigvir: Retrospective studies suggest improved survival rates for early-stage melanoma patients in Latvia when used post-surgery.
Challenges and Future Directions
Despite the potential, several hurdles remain. The innate and adaptive immune systems frequently clear the virus before it can reach the target site, especially during intravenous delivery. Furthermore, there are biosafety concerns regarding the use of live viruses in immunocompromised patients.
The retraction of this specific article underscores the need for continued, rigorous research. Future work must focus on large-scale, reproducible Phase III trials and the optimization of combination strategies—particularly pairing OVs with checkpoint inhibitors to increase T-cell infiltration in non-responsive patients.
Summary updated